Reviewing ChemoCentryx (CCXI) and Alexion Pharmaceuticals (ALXN)
ChemoCentryx (NASDAQ: CCXI) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.
Valuation and Earnings
This table compares ChemoCentryx and Alexion Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|ChemoCentryx||$26.31 million||12.61||-$30.76 million||($0.62)||-10.98|
|Alexion Pharmaceuticals||$3.41 billion||9.00||$1.34 billion||$2.31||59.54|
Alexion Pharmaceuticals has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
49.4% of ChemoCentryx shares are held by institutional investors. Comparatively, 90.7% of Alexion Pharmaceuticals shares are held by institutional investors. 26.8% of ChemoCentryx shares are held by company insiders. Comparatively, 4.4% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current recommendations and price targets for ChemoCentryx and Alexion Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Alexion Pharmaceuticals has a consensus price target of $157.13, suggesting a potential upside of 14.24%. Given Alexion Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Alexion Pharmaceuticals is more favorable than ChemoCentryx.
Risk and Volatility
ChemoCentryx has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.
This table compares ChemoCentryx and Alexion Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Alexion Pharmaceuticals beats ChemoCentryx on 11 of the 14 factors compared between the two stocks.
ChemoCentryx Company Profile
ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.